Description

NovoRapid (Insulin Aspart) – Rapid-Acting Insulin Analog (Rx)

NovoRapid (insulin aspart) is a rapid-acting insulin analog indicated for the treatment of type 1 and type 2 diabetes mellitus. It is designed to mimic physiological insulin response during meals by providing rapid onset of action, allowing effective control of postprandial (after-meal) blood glucose levels.

buy NovoRapid without prescription

We sell over-the-counter NovoRapid medicine
livraison rapide, discrète et fiable
Paiement rapide et sécurisé
faire des achats en toute discrétion sans laisser de traces

Insulin aspart differs structurally from human insulin, enabling faster absorption after subcutaneous injection. It facilitates glucose uptake into muscle and adipose tissue, suppresses hepatic glucose production, and regulates carbohydrate metabolism.

NovoRapid is commonly used as part of a basal-bolus insulin regimen, in combination with intermediate- or long-acting insulin.

Key Details

• Active Ingredient: Insulin aspart
• Drug Class: Rapid-acting insulin analog
• Indications:
  • Type 1 diabetes mellitus
  • Type 2 diabetes mellitus
• Mechanism of Action: Promotes glucose uptake and reduces blood glucose levels
• Onset of Action: ~10–20 minutes
• Peak Effect: ~1–3 hours
• Duration of Action: ~3–5 hours
• Prescription Status: Prescription-only medicine

Cahier des charges

• Dosage Forms:
  • Solution for injection (vials, cartridges, prefilled pens such as FlexPen® / FlexTouch®)
• Strength: Typically 100 units/mL (U-100)
• Administration Routes:
  • Subcutaneous injection
  • Continuous subcutaneous insulin infusion (CSII – insulin pump)
• Timing: Inject immediately before meals or shortly after eating
• Metabolism: Proteolytic degradation in liver, kidneys, and muscle
• Half-Life: ~1 hour (functional duration depends on absorption)
• Storage:
  • Unopened: Refrigerated (2°C–8°C)
  • In-use: Room temperature for a limited period (per manufacturer guidance)

Dosage et administration

• Dose is individualized based on blood glucose monitoring, diet, and activity
• Typically used in multiple daily injection (MDI) regimens
• Can be combined with long-acting (basal) insulin
• Frequent blood glucose monitoring is essential

Compatibilité / Utilisation appropriée

• Patients with type 1 or type 2 diabetes requiring insulin therapy
• Ideal for mealtime glucose control
• Suitable for use with insulin pumps (CSII systems)
• Can be combined with oral antidiabetic agents or basal insulin
• Requires medical supervision and dose adjustment

Contre-indications

• Hypoglycaemia
• Hypersensitivity to insulin aspart or excipients

Warnings & Precautions

• Risk of hypoglycaemia (most common adverse effect)
• Monitor blood glucose levels regularly
• Adjust doses with changes in diet, exercise, illness, or medication
• Rotate injection sites to prevent lipodystrophy
• Use caution in renal or hepatic impairment

Effets indésirables

• Hypoglycaemia
• Injection site reactions
• Weight gain
• Lipodystrophy with repeated use

Interactions médicamenteuses

• Increased hypoglycaemia risk with other antidiabetic agents
• Reduced insulin requirement with ACE inhibitors, alcohol
• Increased glucose levels with corticosteroids, beta-agonists

Why Choose NovoRapid?

NovoRapid provides fast, reliable post-meal glucose control, making it an essential component of modern insulin therapy. Its rapid onset and flexible dosing allow patients to better match insulin delivery with food intake, improving overall glycaemic management.